Oxford University Innovation
Oxford University Innovation (OUI) is the wholly-owned technology transfer subsidiary of the University of Oxford, commercializing Oxford research through IP licensing, spinout formation, and consulting services across life sciences, quantum computing, AI, and clean technology since 1987.
- Company typePrivate
- Founded1987
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Oxford University Innovation does
Oxford University Innovation (OUI) is a private limited company and wholly-owned subsidiary of the University of Oxford that has served as the university's technology transfer and innovation commercialization arm since 1987. The organization identifies, protects, and commercializes intellectual property generated by Oxford researchers across the university's four academic divisions, providing services spanning IP protection, licensing, spinout company formation, and consulting facilitation. In FY 2024/25, OUI recorded 279 invention disclosures and 961 consulting enquiries, with activities generating £18.5 million in royalty and consulting income distributed to the University, researchers, and contractual rights holders. The company employs 51–100 staff at its Oxford headquarters at Buxton Court and operates as the sole gateway between Oxford research output and external commercial channels.
OUI operates the University Challenge Seed Fund (UCSF), the UK's longest continuously running proof-of-concept fund, which has invested £18.5 million across 316 projects over 25 years and is credited with supporting 97 spinouts (40% of Oxford's 248 total spinouts since 2000). UCSF-backed companies have collectively raised £2.97 billion in external funding, with seven reaching public-market listings. Revenue streams combine licensing royalties, equity stakes managed on behalf of the University in spinout companies, consulting service facilitation connecting clients to more than 6,500 Oxford experts from over 50 departments, and tiered subscription income from the Oxford Innovation Society membership programme (£1,500 to £10,500 per year across SME, Corporate, and Large Corporate tiers).
Notable commercial outcomes include the October 2025 acquisition of OrganOx by Terumo Corporation for $1.5 billion (the largest Oxford spinout exit on record), the acquisition of Oxford Ionics by IonQ for $1.075 billion, and Samsung Electronics's acquisition of Oxford Semantic Technologies. OUI has facilitated more than 350 company creations since 1987 and manages a portfolio of over 2,200 patents filed since 2000. The organization also licenses validated clinical outcome assessments (BVAS, VDI, Steroid PRO, AAV-PRO, GCA-PRO) and runs translational funding programmes including the University Challenge Seed Fund. Leadership comprises Dr Mairi Gibbs as permanent CEO (from June 2024) and Jaci Barnett as COO (from September 2024), under the chairmanship of Baroness Nicola Blackwood.
Oxford University Innovation firmographics
Firmographics- Name
- Oxford University Innovation
- Legal name
- Oxford University Innovation Limited
- Website
- https://innovation.ox.ac.uk
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Oxford University Innovation (OUI) is the wholly-owned technology transfer subsidiary of the University of Oxford, commercializing Oxford research through IP licensing, spinout formation, and consulting services across life sciences, quantum computing, AI, and clean technology since 1987.
- Ownership category
- akta.pro rank
Oxford University Innovation industry classification
Industry- Product category
- Technology Transfer Services
- NAICS
- Colleges, Universities, and Professional Schools (61131), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Patent Owners & Lessors (6794), Services-Management Consulting Services (8742), Investment Advice (6282)
- akta.pro primary industry
- Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)
- akta.pro secondary industries
- STEM-Focused Research Universities (Engineering & Applied Sciences) (EDAHABAB), Technical Universities with Entrepreneurship & Incubation Focus (EDAHAEAH)
Keywords
Where Oxford University Innovation is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Oxford University Innovation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Licensing Revenue: Royalty and licensing income from technologies licensed to industry partners, with distributions to University, researchers and third parties with contractual revenue sharing rights
- Equity Stakes in Spinouts: Financial returns generated through company creation, with OUI managing University's equity stakes in spinouts; revenue shared with researchers and departments
- Consulting Services: Facilitation of Oxford expert consultants to external organizations, providing access to over 6,500 experts from more than 50 departments
- Oxford Innovation Society Membership: Annual membership fees from three tiers: SME (£1,500+ VAT), Corporate (£8,000+ VAT), Large Corporate (£10,500+ VAT)
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | SME membership for organizations with annual income under £5m |
| Subscription | Annual | Corporate membership for organizations with annual income £5m-£25m |
| Subscription | Annual | Large Corporate membership for organizations with annual income over £25m |
| Other | Pay-as-you-go | University Challenge Seed Fund awards |
| Other | Annual | Licensing & Ventures Associate position |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Oxford University Innovation product offering
Product offeringCore offering
Oxford University Innovation is the technology transfer and innovation partner of the University of Oxford, providing services across IP identification and protection, spinout company creation and growth, technology licensing, and academic consultancy facilitation. The organization connects Oxford's 6,500+ researchers with industry partners, investors, and external organizations seeking access to Oxford innovations and expertise. Revenue is generated through licensing royalties, equity stakes in spinout companies, consultancy fees, and membership subscriptions.
Product overview
Oxford University Innovation (OUI) is the technology transfer organization for the University of Oxford, offering a portfolio of licensing opportunities, clinical outcome assessments, proof-of-concept funding, and innovation ecosystem services. OUI's Clinical Outcomes team manages a suite of validated patient-reported outcome measures (COAs) including Steroid PRO, AAV-PRO, GCA-PRO, BVAS, VDI, and Mini-OCS, available for licensing. The organization also facilitates licensing of Oxford research technologies including the Universal HLA-E mRNA vaccine platform, HPV immunotherapy platform, and TCR therapies. OUI operates the University Challenge Seed Fund (UCSF), provides membership through the Oxford Innovation Society, and supports spinout companies including OrganOx metra for liver transplantation.
Differentiator
Problem solved
Functional benefit
Brands
- Oxford Innovation Society (OIS): A collaborative forum managed and facilitated by OUI where Oxford researchers, founders, investors, and industry partners connect to share ideas, build relationships, and explore new opportunities.
- University Challenge Seed Fund (UCSF)
Products and services
- Steroid PRO The first validated and reliable patient-reported outcome measure (PRO) designed specifically to evaluate the well-being of patients undergoing glucocorticoid therapy for rheumatic diseases. A 15-item scale with 4 domains: social impact, impact on appearance, psychological impact, and treatment concerns. Available for licensing.
- AAV-PRO (ANCA-associated vasculitis PRO) A disease-specific patient-reported outcome measure for ANCA-associated vasculitis, used to assess health-related quality of life and disease burden experienced by patients. Available for licensing.
- GCA-PRO (Giant Cell Arteritis PRO) A validated outcome measure for use in clinical trials, observation studies and clinical practice to measure symptoms and impact on health-related quality of life in patients with Giant Cell Arteritis. Available for licensing.
- BVAS (Birmingham Vasculitis Activity Score) The gold-standard tool for assessing vasculitis disease activity across various organ systems, providing reliable measures for use in clinical trials and studies, helping predict long-term outcomes like relapse and mortality. Available for licensing.
- VDI (Vasculitis Damage Index) An evaluation tool that measures irreversible damage caused by vasculitis or its treatments, offering insights into long-term patient prognosis and quality of life. Available for licensing.
- Mini-Oxford Cognitive Screen (Mini-OCS) A rapid, stroke-specific cognitive screening tool for primary and community care, providing a sensitive 7-9 minute assessment of cognitive function. Available for licensing.
- Statin Side Effects Risk Calculator A calculator developed by University of Oxford researchers that estimates individual risk of serious muscle disorders from statins, based on data from 5.6 million people. Available for licensing.
- Universal HLA-E mRNA Vaccine Platform Technology utilizing mRNA-encoded HLA-E-beta2 microglobulin-peptide single-chain trimers to directly present target antigens on cell surfaces, enabling robust HLA-E presentation. Available for licensing.
- Universal HLA-E Targeted HPV Immunotherapy Platform Technology comprising antibodies, TCRs, and CAR-T cells targeting HPV-derived peptides presented by the non-polymorphic HLA-E molecule for universal immunotherapy applications. Available for licensing.
- HLA-E Enabled Universal Wilm's Tumour-1 TCR Therapy Patented technology covering T cell receptors (TCRs) specific for a WT1 peptide presented by HLA-E, alongside nucleic acids and associated components. Available for licensing.
- University Challenge Seed Fund (UCSF) The UK's longest continuously running proof-of-concept fund supporting early-stage projects with market potential, investing between £2,500 and £250,000. Managed by OUI for Oxford University researchers with quarterly calls.
- Oxford Innovation Society A collaborative forum connecting Oxford researchers, founders, investors, and industry partners. Membership options include SME (£1,500/year), Corporate (£8,000/year), and Large Corporate (£10,500/year).
- EIT Pathogena A genomic analysis tool launched by the Ellison Institute of Technology for detecting and analyzing Mycobacterium tuberculosis and other pathogens. Built on Oracle cloud technology.
Quantifiable outcome
- 97 spinouts created with UCSF support, representing 40% of Oxford's total 248 spinouts since 2000
- +4 more outcomes
Companies that use Oxford University Innovation
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles4 records
Oxford University Innovation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Oxford University Innovation partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and minor.
- University of OxfordcoreOUI works as the innovation partner of the University of Oxford, using commercial expertise to turn academic knowledge and research into real-world applications
- TenUmajorInternational collaboration of ten technology transfer offices (TTOs) of world-leading universities; OUI holds presidency for 2026
- Koa HealthmajorCommercial licence partnership for four online mental health therapies (anxiety, PTSD) developed by Oxford experts, now available across NHS Trusts
- Ellison Institute of TechnologymajorMultidisciplinary research and innovation organization developing scalable solutions to global challenges through partnership with University of Oxford
- Apollo TherapeuticsmajorDrug discovery and development collaboration with University of Oxford, bringing capital and therapeutic development expertise to Oxford researchers
- LSE InnovationminorCo-leading training and knowledge dissemination for Impact U (formerly Impact 12) social venture consortium with OUI
- Cambridge EnterpriseminorPart of Impact U consortium for university social ventures, collaborating on Pathfinder Awards and knowledge-sharing ecosystem
- NIHR Oxford Biomedical Research CentreminorProvided early support for OrganOx clinical development
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
Oxford University Innovation competitors and assessment
Company assessmentDirect peers
- Cambridge Enterprise: University of Cambridge's technology transfer office, the closest UK peer to OUI. Operates the same mix of spinout creation, licensing, and proof-of-concept funding (Cambridge Enterprise Seed Funds) at a similarly prestigious research university.
- MIT Technology Licensing Office: MIT's TTO handling invention disclosures, patenting, and licensing for one of the world's highest-volume commercialization universities. Comparable model and global licensing footprint to OUI's, with comparable depth in STEM research.
- Stanford Office of Technology Licensing: Stanford's TTO is widely regarded as the high-water mark for university spinout creation, including Google and biotech origins. Direct global peer to OUI given its emphasis on equity retention and high-value exits.
- UCL Business: UCL's commercialization arm operating UCLB, delivering spinout creation, licensing and consultancy at a major UK research university. Closely comparable business model and customer base (researchers, licensees, investors) to OUI.
- Imperial College Innovations: Imperial College London's TTO focused on STEM spinouts in deep tech and health. Direct UK peer to OUI with a comparable mix of licensing, equity stakes and seed funding through the Imperial College Innovation Fund.
- Columbia Technology Ventures: Columbia University's TTO managing IP licensing and spinout formation, including startups from Columbia's engineering, medical, and data science faculties. Comparable scale and operating model to OUI.
Broad incumbents
- IP Group plc: Publicly listed UK firm specializing in commercializing university-derived IP via long-term equity investments and spinout creation. Competes with OUI for the same UK university deal flow, but operates as an investment firm rather than an in-house TTO.
Others
- Oxford Science Enterprises: Dedicated investment company backing Oxford spinouts, partnered with OUI through UCSF (including a £3m top-up in 2018). Ecosystem participant rather than direct competitor - co-creates and co-funds the spinouts OUI originates.
- Apollo Therapeutics: Drug discovery and development collaboration between Oxford, Cambridge, Imperial, UCL and three global pharma companies. Strategic partner rather than competitor - adds downstream therapeutic development capability to OUI-licensed academic research.
- TenU: International consortium of ten leading university TTOs (including OUI) collaborating on best-practice, training and shared services. Ecosystem participant rather than a competitor; OUI holds the consortium presidency for 2026.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Oxford University Innovation social profiles
Digital presenceOxford University Innovation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxford University Innovation leadership team
Management profileNumber of profiles
Profiles4 records
Oxford University Innovation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxford University Innovation M&A and investment
M&A and investmentM&A
Investments65 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxford University Innovation
What does Oxford University Innovation do?
Oxford University Innovation is the technology transfer and innovation partner of the University of Oxford, providing services across IP identification and protection, spinout company creation and growth, technology licensing, and academic consultancy facilitation. The organization connects Oxford's 6,500+ researchers with industry partners, investors, and external organizations seeking access to Oxford innovations and expertise. Revenue is generated through licensing royalties, equity stakes in spinout companies, consultancy fees, and membership subscriptions.
Is Oxford University Innovation a public or private company?
Oxford University Innovation is a private company. It is classified as corporate owned and is currently operating.
When was Oxford University Innovation founded?
Oxford University Innovation was founded in 1987. It employs 51 to 100 people.
Where is Oxford University Innovation based?
Oxford University Innovation is headquartered in Oxford, United Kingdom, in the Europe region.
How does Oxford University Innovation make money?
Four revenue lines are on record. Licensing Revenue is the primary driver. The others are equity Stakes in Spinouts, consulting Services and oxford Innovation Society Membership.
Who are Oxford University Innovation's main competitors?
Direct peers on record are Cambridge Enterprise, MIT Technology Licensing Office, Stanford Office of Technology Licensing, UCL Business, Imperial College Innovations and Columbia Technology Ventures. IP Group plc is listed as a broad incumbent. Others are Oxford Science Enterprises, Apollo Therapeutics and TenU.
Does Oxford University Innovation have an API?
No public API is recorded for Oxford University Innovation.
What industry is Oxford University Innovation in?
Oxford University Innovation's product category is Technology Transfer Services. Its primary akta.pro industry code is EDAHABAH, Technology Transfer & Innovation-Driven Research Universities (High Commercialization), with a secondary code of EDAHABAB, STEM-Focused Research Universities (Engineering & Applied Sciences). Its NAICS code is 61131 and its SIC code is 6794.